At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SGMT Sagimet Biosciences Inc.
Pre-Mkt 02-26 08:28:21 EST
6.13
+0.21
+3.55%
盘前6.04
-0.09-1.47%
08:26 EST
High6.25Low5.90Vol406.50K
Open6.00D1 Closing5.92Amplitude5.85%
Mkt Cap199.36MTradable Cap138.70MTotal Shares32.52M
T/O2.49MT/O Rate1.80%Tradable Shares22.63M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
GlobeNewswire  ·  02-25 20:00
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
Top Sagimet Executives Quietly Unload Shares in Coordinated Insider Move
TIPRANKS  ·  02-13
Top Sagimet Executives Quietly Unload Shares in Coordinated Insider Move
Sagimet Biosciences nimmt an Investorenkonferenzen von Guggenheim und Oppenheimer teil
Reuters  ·  02-05
Sagimet Biosciences nimmt an Investorenkonferenzen von Guggenheim und Oppenheimer teil
After Clearing Up Acne, Sagimet Stock Rises -- Barrons.com
Dow Jones  ·  02-04
After Clearing Up Acne, Sagimet Stock Rises -- Barrons.com
Wall Street's Top Analysts Issue Latest Ratings: Adobe Downgraded, Palantir Upgraded
Deep News  ·  02-03
Wall Street's Top Analysts Issue Latest Ratings: Adobe Downgraded, Palantir Upgraded
Sagimet Biosciences Price Target Maintained With a $29.00/Share by HC Wainwright & Co.
Dow Jones  ·  02-03
Sagimet Biosciences Price Target Maintained With a $29.00/Share by HC Wainwright & Co.
Sagimet Biosciences initiated with a Buy at Guggenheim
TIPRANKS  ·  02-03
Sagimet Biosciences initiated with a Buy at Guggenheim
Sagimet Biosciences price target raised to $37 from $29 at Clear Street
TIPRANKS  ·  02-03
Sagimet Biosciences price target raised to $37 from $29 at Clear Street
Analysts Conflicted on These Healthcare Names: Sagimet Biosciences, Inc. Class A (SGMT) and Siemens Healthineers AG (OtherSEMHF)
TIPRANKS  ·  02-03
Analysts Conflicted on These Healthcare Names: Sagimet Biosciences, Inc. Class A (SGMT) and Siemens Healthineers AG (OtherSEMHF)
BRIEF-Sagimet Says Denifanstat Shows Improvements In Efficacy Endpoints Beyond 12 Weeks
Reuters  ·  02-02
BRIEF-Sagimet Says Denifanstat Shows Improvements In Efficacy Endpoints Beyond 12 Weeks
Sagimet Biosciences announces license partner Ascletis issues results for ASC40
TIPRANKS  ·  02-02
Sagimet Biosciences announces license partner Ascletis issues results for ASC40
Sagimet Biosciences Reports Positive 52-Week Phase 3 Results for Denifanstat in Moderate to Severe Acne
Reuters  ·  02-02
Sagimet Biosciences Reports Positive 52-Week Phase 3 Results for Denifanstat in Moderate to Severe Acne
Sagimet Announces Positive 52-Week Data From License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of Asc40 (Denifanstat) Tablets in Patients With Moderate to Severe Acne
THOMSON REUTERS  ·  02-02
Sagimet Announces Positive 52-Week Data From License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of Asc40 (Denifanstat) Tablets in Patients With Moderate to Severe Acne
Sagimet Biosciences Inc - Denifanstat Well Tolerated With Teaes Incidence Rate of 5% or More
THOMSON REUTERS  ·  02-02
Sagimet Biosciences Inc - Denifanstat Well Tolerated With Teaes Incidence Rate of 5% or More
Sagimet Biosciences Inc - Denifanstat Shows Improvements in Efficacy Endpoints Beyond 12 Weeks
THOMSON REUTERS  ·  02-02
Sagimet Biosciences Inc - Denifanstat Shows Improvements in Efficacy Endpoints Beyond 12 Weeks
Multiple Shots on Goal: Sagimet’s Differentiated MASH Combo and Acne Franchise Underpin Buy Rating and Favorable Risk‑Reward
TIPRANKS  ·  02-02
Multiple Shots on Goal: Sagimet’s Differentiated MASH Combo and Acne Franchise Underpin Buy Rating and Favorable Risk‑Reward
Ascletis Pharma New Drug Application for Denifanstat Accepted by China National Medical Products Administration
Reuters  ·  01-29
Ascletis Pharma New Drug Application for Denifanstat Accepted by China National Medical Products Administration
Sagimet Biosciences Initiated at Equal-Weight by Barclays
Dow Jones  ·  01-28
Sagimet Biosciences Initiated at Equal-Weight by Barclays
Barclays Initiates Coverage on Sagimet Biosciences With Equal Weight Rating, $8 Price Target
MT Newswires Live  ·  01-28
Barclays Initiates Coverage on Sagimet Biosciences With Equal Weight Rating, $8 Price Target
Sagimet Biosciences: Advancing FASN Inhibitor Pipeline and Multi-Indication Opportunities Support Buy Rating and $26 Target
TIPRANKS  ·  01-10
Sagimet Biosciences: Advancing FASN Inhibitor Pipeline and Multi-Indication Opportunities Support Buy Rating and $26 Target

Introduction

Company Name.
Sagimet Biosciences Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
Issue price:
--